文献速递神经肿瘤

胶质母细胞瘤相关临床试验早期终止因素分析

Analysis of factors leading to early termination in glioblastoma-related clinical trials.
PubMed 文献 · J Neurooncol · 2022-06-01

该研究检索 ClinicalTrials.gov 中 2003 至 2020 年胶质母细胞瘤(GBM)相关已完成与已终止临床试验,比较两组特征以识别早期终止相关因素。共纳入 886 项试验,175 项(19.8%)在完成前终止,最常见原因为受试者招募困难(63 项,占终止试验 36.0%)。多因素分析显示,主要目的为诊断的试验相对于治疗试验与早期终止相关(OR=2.952,p=0.001)。

要点

  • 886 项 GBM 相关试验中 175 项(19.8%)在完成前终止。
  • 终止最常见原因为受试者招募困难,占终止试验的 36.0%(63 项)。
  • 主要目的为诊断的试验较治疗试验更易早期终止(OR=2.952,p=0.001)。

核心结论

  • GBM 治疗干预临床试验的早期终止与诊断类试验相对于治疗类试验相关。
  • 受试者招募困难是早期终止最常报告的原因。
  • 设计 GBM 相关临床试验时应考虑试验终止的预测因素以减少早期终止的几率。

研究设计与样本

  • 基于 ClinicalTrials.gov 的回顾性分析,检索 2003 年至 2020 年所有已完成和已终止的 GBM 相关临床试验。
  • 共纳入 886 项已完成和已终止的 GBM 相关试验。
  • 采用 Pearson 卡方进行单因素分析,多因素 logistic 回归识别早期终止的独立预测因素。

主要发现

  • 886 项试验中 175 项(19.8%)在完成前终止。
  • 终止最常见原因为受试者招募困难,占终止试验的 63 项(36.0%)。
  • 主要目的为诊断的试验相对于治疗试验与试验终止相关(OR=2.952,p=0.001)。

临床怎么用

  • 作者认为,设计 GBM 相关临床试验时应考虑试验终止的预测因素,以尽量减少早期终止的几率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Terminated clinical trials are an inefficient use of financial, patient, and administrative resources. We reviewed ClinicalTrials.gov for completed and terminated clinical trials for glioblastoma multiforme (GBM) and compared reported characteristics of completed and terminated trials to identify factors associated with early trial termination. METHODS: ClinicalTrials.gov was queried to identify all completed and terminated GBM-related clinical trials. Trial characteristics were examined and the reason for trial termination was determined. Univariate analysis by Pearson's chi-square and a multivariate logistic regression were performed to identify independent predictors of early trial termination. RESULTS: We identified 886 completed and terminated GBM-related trials between 2003 and 2020. Of these, 175 (19.8%) were terminated prior to completion. The most common reason for termination was participant accrual difficulties, accounting for 63 (36.0%) terminated trials. Trial termination was associated with trials that reported a primary purpose of diagnosis relative to treatment (OR = 2.952, p = 0.001). CONCLUSION: Early termination of clinical trials investigating interventions for the treatment of GBM is associated with diagnostic trials relative to therapeutic trials. Patient accrual difficulties are the most commonly identified reason for early trial termination. Predictors of trial termination should be considered when designing GBM-related clinical trials to minimize the odds of early trial termination.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Shah HA, Mishra A, Gouzoulis MJ, et al. Analysis of factors leading to early termination in glioblastoma-related clinical trials. J Neurooncol. 2022. PMID: 35648307. doi:10.1007/s11060-022-04039-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。